RxDoctor Payments Data

Pekkakuzhiyil Mathew, MD

Internal Medicine · Bluffton, INNPI 1578507539

Payments from drug & device makers

$6,047in general payments, 2019–2025

Across 373 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$786
  • Lilly USA, LLC$715
  • AstraZeneca$715
  • Novo Nordisk$483
  • Bayer$391
  • Novartis$278
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,041100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,047 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$69,509
Medicare patients
404
Services billed
781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban741$404,757
OzempicSemaglutide131$173,788
XareltoRivaroxaban238$139,466
JardianceEmpagliflozin148$138,953
GemtesaVibegron310$132,047
TrulicityDulaglutide84$95,197
JanuviaSitagliptin Phosphate97$82,690
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$77,890
TradjentaLinagliptin146$71,150
FarxigaDapagliflozin Propanediol42$59,004
LinzessLinaclotide82$56,728
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog58$47,174
Tresiba Flextouch U-100Insulin Degludec63$46,012
MyrbetriqMirabegron57$41,632
Janumet XrSitagliptin Phos/Metformin Hcl24$32,001

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$169$416,627761 claims
Boehringer IngelheimJardiance, Tradjenta$174$210,103294 claims
Novo NordiskOzempic$483$173,788131 claims
Johnson & JohnsonXarelto$150$139,466238 claims
Sumitomo Pharma America, Inc.Gemtesa$145$132,047310 claims
Lilly USA, LLCTrulicity, Mounjaro$715$121,326108 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$259$116,620156 claims
MerckJanuvia, Janumet Xr$106$114,690121 claims
AbbVieLinzess, Namzaric, Restasis$786$81,078135 claims
AstraZenecaFarxiga, Breztri Aerosphere$715$75,02356 claims
Astellas Pharma US IncMyrbetriq$63$41,63257 claims
Otsuka America Pharmaceutical, Inc.Rexulti$185$19,22013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Bluffton

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →